Brief: Ascendis Announces Oral Presentation Of Week 104 Data From Its Pivotal Trial Of Transcon® CNP (Navepegritide) At Isds 2026
25/08/2026 21:06
BRIEF-Ascendis Announces Oral Presentation Of Week 104 Data From Its Pivotal Trial Of Transcon® CNP (Navepegritide) At Isds 2026 Aug 25 (Reuters) - Ascendis Pharma A/S ASND.O:
ASCENDIS ANNOUNCES ORAL PRESENTATION OF WEEK 104 DATA FROM ITS PIVOTAL TRIAL OF TRANSCON® CNP (NAVEPEGRITIDE) AT ISDS 2026
Source text: ID:nGNX1YwZB9
Further company coverage: ASND.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascendis Pharma A/S
See all newsAscendis Pharma tumbles on Novo Nordisk collab termination
BioMarin climbs on global patent settlement with Ascendis
Brief: Ascendis Announces Oral Presentation Of Week 104 Data From Its Pivotal Trial Of Transcon® CNP (Navepegritide) At Isds 2026
Brief: Eyconis Announces Initiation Of First-In-Human Clinical Trial Of Eyc-0305 In Treatment-Naïve Wet Age-Related Macular Degeneration Patients
Ascendis Pharma A/S reports results for the quarter ended June 30 - Earnings Summary